recently, 1 such specific drug, GLP-1 RA, has received significant attention due to its promising potential as a weight loss agent
Oral GLP-1 RAs are also under development, and early data show similar weight loss efficacy to semaglutide 2.4 mg [84], which could improve convenience and potentially reduce costs through improved manufacturing and distribution efficiency
An innovator may offer a biosimilar developer a license to the entire patent portfolio, including CIP-derived patents, in exchange for a delayed launch date
Whether youre focused on weight loss, diabetes, or both, you deserve care that feels safe, personalized, and easy to understand